Last reviewed · How we verify
NCT03325634
Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer
Phase 1 trial testing Laboratory Biomarker Analysis in Recurrent Endometrial Serous Adenocarcinoma in 15 participants. Completed in 20 October 2025.
10 November 2020
Quick facts
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 27 October 2017 |
| Primary completion | 10 November 2020 |
| Estimated completion | 20 October 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Laboratory Biomarker Analysis — full drug profile →
- Quality-of-Life Assessment
- Questionnaire Administration
- Stereotactic Body Radiation Therapy — full drug profile →
Conditions studied
- Recurrent Endometrial Serous Adenocarcinoma — all drugs for Recurrent Endometrial Serous Adenocarcinoma →
- Recurrent Fallopian Tube Carcinoma — all drugs for Recurrent Fallopian Tube Carcinoma →
- Recurrent Ovarian Carcinoma — all drugs for Recurrent Ovarian Carcinoma →
- Recurrent Primary Peritoneal Carcinoma — all drugs for Recurrent Primary Peritoneal Carcinoma →
Sponsor
University of Colorado, Denver
Who can join
18 and older, female only, with Recurrent Endometrial Serous Adenocarcinoma or Recurrent Fallopian Tube Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with ovarian or uterine cancer that has come back. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
Robin TP, Hu J, Jones BL, Patton T, et al · · 2025 · cited 2× · PMID 40839922 · DOI 10.1016/j.ygyno.2025.07.023
Verify or expand the search:
- PubMed search for NCT03325634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Laboratory Biomarker Analysis
Trials testing the same drug.
- NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
- NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
- NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
- NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
- NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting
Other recruiting trials for Recurrent Endometrial Serous Adenocarcinoma
Currently open trials in the same condition.
- NCT05231122 — Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re · Phase 2 · recruiting
- NCT05870761 — Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma · Phase 2 · active not recruiting
- NCT03914612 — Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carbopl · Phase 3 · active not recruiting
- NCT03120624 — VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · Phase 1 · active not recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
- NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
- NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
- NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
- NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03325634 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
- Last refreshed: 23 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03325634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing